Tags

Type your tag names separated by a space and hit enter

Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.
J Infect. 2020 10; 81(4):647-679.JI

Authors+Show Affiliations

Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: fbrzcantini@gmail.com.Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy.Rheumatology department, Azienda USL Toscana Centro, Hospital of Prato, Italy.Sanitary Direction, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: daniela.matarrese@uslcentro.toscana.it.II Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: massimoedoardo.dinatale@uslcentro.toscana.it.II Division of Internal Medicine, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: pamela.lotti@uslcentro.toscana.it.Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Prato, Italy. Electronic address: donatella.aquilini@uslcentro.toscana.it.Department of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: giancarlo.landini@uslcentro.toscana.it.Department of Medical Specialties, Division of Internal Medicine, Azienda USL Toscana Centro, S.Maria Nuova Hospital, Florence, Italy. Electronic address: barbara.cimolato@uslcentro.toscana.it.Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: massimoantonio.dipietro@uslcentro.toscana.it.Division of Infectious Diseases, Azienda USL Toscana Centro, Hospital of Pistoia, Italy. Electronic address: michele.trezzi@uslcentro.toscana.it.Rheumatology Unit, AO SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy. Electronic address: pstobbione@ospedale.al.it.Division of Internal Medicine, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Fano-Pesaro, Italy. Electronic address: gabriele.frausini@ospedalimarchenord.it.Clinical epidemiology Unit, National Institute for Infectious Diseases, Lazzaro Spallanzani, Rome, Italy. Electronic address: assunta.navarra@inmi.it.Clinical Division of Infectious Diseases, National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, Rome, Italy. Electronic address: emanuele.nicastri@inmi.it.Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy. Electronic address: gsotgiu@uniss.it.Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI), IRCCS, Rome, Italy. Electronic address: delia.goletti@inmi.it.

Pub Type(s)

Letter
Comment

Language

eng

PubMed ID

32592703

Citation

Cantini, Fabrizio, et al. "Beneficial Impact of Baricitinib in COVID-19 Moderate Pneumonia; Multicentre Study." The Journal of Infection, vol. 81, no. 4, 2020, pp. 647-679.
Cantini F, Niccoli L, Nannini C, et al. Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020;81(4):647-679.
Cantini, F., Niccoli, L., Nannini, C., Matarrese, D., Natale, M. E. D., Lotti, P., Aquilini, D., Landini, G., Cimolato, B., Pietro, M. A. D., Trezzi, M., Stobbione, P., Frausini, G., Navarra, A., Nicastri, E., Sotgiu, G., & Goletti, D. (2020). Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. The Journal of Infection, 81(4), 647-679. https://doi.org/10.1016/j.jinf.2020.06.052
Cantini F, et al. Beneficial Impact of Baricitinib in COVID-19 Moderate Pneumonia; Multicentre Study. J Infect. 2020;81(4):647-679. PubMed PMID: 32592703.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. AU - Cantini,Fabrizio, AU - Niccoli,Laura, AU - Nannini,Carlotta, AU - Matarrese,Daniela, AU - Natale,Massimo Edoardo Di, AU - Lotti,Pamela, AU - Aquilini,Donatella, AU - Landini,Giancarlo, AU - Cimolato,Barbara, AU - Pietro,Massimo Antonio Di, AU - Trezzi,Michele, AU - Stobbione,Paolo, AU - Frausini,Gabriele, AU - Navarra,Assunta, AU - Nicastri,Emanuele, AU - Sotgiu,Giovanni, AU - Goletti,Delia, Y1 - 2020/06/24/ PY - 2020/06/19/received PY - 2020/06/20/accepted PY - 2020/6/28/pubmed PY - 2020/9/30/medline PY - 2020/6/28/entrez KW - Baricitinib KW - COVID-19 KW - JAK1/2 KW - Pneumonia KW - Retrospective study KW - SARS-Co-V2 SP - 647 EP - 679 JF - The Journal of infection JO - J Infect VL - 81 IS - 4 SN - 1532-2742 UR - https://www.unboundmedicine.com/medline/citation/32592703/Beneficial_impact_of_Baricitinib_in_COVID_19_moderate_pneumonia L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-4453(20)30433-3 DB - PRIME DP - Unbound Medicine ER -